Company Specifications: Big Booming Business

At first we we decided to post this as a document, but since I can't seem to figure out to how or where to post a document, I'm going to post this as an informal table. The specifications are listed below and possibly subject to change, or slight modification:

COMPONENT	PRICE/DESCRIPTION
ADVERTISING	Advertising costs will include client advertising (for example, in health related professions such as hospitals and nursing homes). Approximately $100,000 will be awarded to this branch of business in order to pursue advertising for the new ORAL PCA. More may be awarded to this business sector when the results arrive from the manufacturing and distribution test trials and analysis of cost-benefits have been taken into account. Advertising strategies include pamphlet mail-outs, client consultations, and product-launch marketing.
TIME TO MARKET	The FDA must first approve of the safety of the design which could take approximately year. The time for the product to get to the market will be approximately 2-3years after the design has been formalized and confirmed; from this point, it will be sent to manufacturing and distribution companies for product analysis and testing. Manufacturing should take six months to come out with a fully functioning version, while trial tests should last about a year. The remaining time should be devoted to analysis of the test trials and perfecting the few prototypes. Distribution should take another six months.
COMPETITION	The competition for ORAL PCAs will include competition from regular PCA (intravenous) companies such as Smiths Medical. Once the product has been out in the market, we will anticipate other versions of the ORAL PCA to be on the market. We foresee similar companies like Smiths Medical to take on ORAL PCA manufacturing and distribution as popularity for the product grows.
BUSINESS STRATEGY	The business strategy for the ORAL PCA will be to target health related professional environments. Prior to the launch and after the product has been cleared for safety features (optimally during the closing of our trial runs that have positive results), we expect to participate in various symposiums and forums in the medical field to promote the product. We hope to attract clients from both hospital settings to more privatized sectors of the health field (nursing homes, private practices etc.) Then we hope to contact interested clients. This will include specific client consultations in order to promote and sell the ORAL PCA. These strategies are included in the advertising costs under product-launch marketing and client consultation.
PRICING	The pricing of the entire ORAL PCA is dependent of the oral medical in the device. The device itself should cost approximately $1000-$2000 dollars each. This does not, however, include accessories and other products or services associated with the device. Accessories and other products will not come out to market until about a year after the device has been fully launched and is successful; this is also dependent on the consumer demand.
MANUFACTURING	The manufacturing costs will include putting the design through a company that will manufacture prototypes and the actual product once it’s ready for the market. Manufacturing costs should be around $500-$750 per ORAL PCA product. Like other medical innovations, government subsidies or grants may help the initial start-up of the project; if this is the case, manufacturing costs may be lower.
DISTRIBUTION	Distribution is tied with the manufacturing company and dependent on that timeline. We hope to distribute these products directly to health care providers as well as clinicians in professional health related fields. The distribution of the product will include a formal verbal and hands-on break-down of how the ORAL PCA works and how to prompt patients on its use. For larger hospital settings, we hope to teach the clinicians and administrators how to use the product during a post-consultation session before distributing this to other patients. This will be included in any fees directed in the distribution costs. These costs should run about $500 dollars per session; it is not optional. Shipping and handling will be directed through the company and this will be an extra $100.
SALES	Around twice the annual sales of other competitors
REPAIR & UPGRADES	Can be sent back in for repair within two years time for free, upgrades include larger versions that can store greater amounts of medication at time
FINANCIAL	Requires investments of $200,000 at least.
REGULATIONS	The product can be distributed to hospitals only.
POLLUTION	It saves a lot of energy that would be expended to other actions. This product saves both time and effort for the patient and the administrators. However, the disposable tips are not that environmentally friendly.
INTELLECTUAL PROPERTY	It is its own line of product, the next closest is Avancen MOD but that is designed for bedside administration only. Therefore, there are exclusive rights to this patent.
PRODUCT LIABILITY	Product liability involves potential problems with manufacturing defects, design defects, and failure to warn of potential failures. This could involve unhygienic mouthpieces, tubes, etc.